Onychomycosis Treatment Market - By Test (Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candida Onychomycosis), By Treatment Type, By Drug Class, By Distribution Channel & Forecast, 2021-2027

Industry trends

Onychomycosis Treatment Market size exceeded USD 4.2 billion in 2020 and is expected to grow at a CAGR of over 5.6% from 2021 to 2027. Increasing prevalence of onychomycosis worldwide, growing awareness about the potential threats of onychomycosis, and the rise in the adoption of drug therapies are some of the prominent factors that drive the market growth. Moreover, rising cases of age-related onychomycosis will further propel the market expansion during the forecast period.
 

To get more details on this report: Request Free Sample PDF
 

The impact of COVID-19 on the market is observed to be negative since a large number of countries adopted lockdown to curb community transmission of the COVID-19 infection. The market witnessed a short-term disruption during the initial days of the COVID-19 pandemic due to the supply chain disruptions and decline in non-urgent in-person clinic visits resulting in a negative impact on the market.
 

Growing prevalence of diabetes in many parts of the world will boost the market progression

Diabetic patients are susceptible to toenail fungus. Much scientific research has been performed to evaluate whether diabetic people experience a greater risk of onychomycosis than those without diabetes. Most of the studies concluded that they do. According to scientific research, approximately one in three people with diabetes are afflicted with onychomycosis. Onychomycosis in diabetic patients is more than a cosmetic nuisance.
 

The outcome from untreated cases may include an increased risk of other foot disorders and limb amputation. Therefore, effective onychomycosis treatment in diabetic individuals is of paramount importance.
 

Distal subungual onychomycosis (DSO) segment will dominate the market revenue

The distal subungual onychomycosis segment dominated more than 68% of the market share in 2020. DSO represents the most common type of onychomycosis. It is also more common in smokers and in those who use shared bathing facilities and occlusive footwear.
 

Increasing availability of oral medication for onychomycosis treatment will foster the market demand

To get more details on this report: Request Free Sample PDF
 

The drug treatment segment accounted for USD 2.5 billion in 2020. The segment growth is high as the oral antifungal agents or drugs have been identified as the most suitable and first-line therapy for onychomycosis. The most commonly used oral drugs for the treatment of onychomycosis are itraconazole, terbinafine, griseofulvin, and ketoconazole. Also, the wide availability of these drugs in pharmacies further augments the industry growth.
 

Rising demand of topical drugs will spur the overall industry expansion

Allylamine segment in the onychomycosis treatment market is projected to showcase 5.4% growth rate through 2027. Allylamines are the most commonly used form of drug class and effective in treating most forms of fungal infections. Naftin and Lamisil are the topical allylamines that are used for onychomycosis treatment. Increasing availability and usage of such drugs will influence the industry revenue in the coming years.
 

Increasing hospital visits for onychomycosis treatment will stimulate the industry progression

The hospital pharmacies distribution channel segment was valued at USD 2.4 billion in 2020 impelled by the higher hospital visits and the availability of medicines in hospital pharmacies. Also, revenue generated through hospital pharmacies is higher as the infected patients generally visit the nearby hospitals for consultation and doctors’ prescriptions.
 

Rising awareness about onychomycosis treatment in North America will enhance the market value

To get more details on this report: Request Free Sample PDF
 

North America onychomycosis treatment market captured 40% of revenue share in 2020 on account of the increasing awareness about onychomycosis infection and the availability of several treatment options in the region. Rising desire for better aesthetic appeal and hygiene also increases the demand for timely clinic visits and early detection of such infections. Effective treatment may reduce the rate of transmission and related morbidities.
 

The industry is flooded with several global companies offering similar products

Some of the prominent players operating in the market include Pfizer Inc., Novartis AG, Johnson & Johnson Services Inc., Medimetriks Pharmaceuticals Inc., Bausch Health Sciences, Galderma Laboratories, Moberg Pharma AB, Dr. Reddy’s Laboratories Ltd, Merz Pharma, Kaken Pharmaceutical Co. Ltd, GlaxoSmithKline plc, and Taro Pharmaceuticals Industries Ltd. These participants are implementing various growth strategies to sustain industry competition.
 

The onychomycosis treatment market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2016 to 2027, for the following segments:

Click here to Buy Section of this Report

Market, By Type, 2016-2027 (USD Million)

• Distal subungual onychomycosis (DSO)
• White superficial onychomycosis (WSO)
• Proximal subungual onychomycosis (PSO)
• Candida onychomycosis
• Others

Market, By Treatment Type, 2016-2027 (USD Million)

• Drug treatment
• Topical therapy

Market, By Drug Class, 2016-2027 (USD Million)

• Allylamine
• Azole
• Griseofulvin
• Others

Market, By Distribution Channel, 2016-2027 (USD Million)

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • UAE
  • South Africa